Notably, the patient maintained stroke-free status for five years on aspirin monotherapy, highlighting the value of antiplatelet therapy in secondary prevention of arterial thrombosis caused by non-criteria antibodies (particularly aβ2GPI IgA) associated APS. This evidence concerns the gene CD79A and stroke disorder.